PMPRB

The PMPRB has released its January 2015 NEWSletter

Topics covered in the NEWSletter include:

• Final 2014 CPI-Based Price-Adjustment Factors: The final CPI figures for 2014 are now available. Of note:
  • The actual CPI-based price-adjustment factor for 2 year (2012) and 3 year (2011) are lower than forecast. As a result, some manufacturers/patentees may have overpriced.
  • The actual CPI-based price-adjustment factor for one year (2013) is the same as forecast.

• 2016 CPI-Based Price-Adjustment Factors for Patented Drug Products: New lagged CPI methodology in effect as of January 1, 2015.  Based on these factors, maximum allowable cumulative price increase is as follows:
  • 4.4% for patented drug products with Canadian sales in 2013
  • 2.9% for patented drug products with Canadian sales in 2014
  • 2.0% for patented drug products with Canadian sales in 2015

The year-over-year price increase cap for the 12-month period ending December 2015 is 3.0%.

•  The Recognized Price Source for Germany is Changing to Lauer-Taxe Effective 2016

Other news include:

• Message from the Executive Director
• New Staff Members
• Notice of Hearing: Soliris and Alexion Pharmaceuticals Inc.
• Voluntary Compliance Undertaking: Gelnique
• Recent Publications
• Coming Soon: Public Drug Plan Expenditure Report
• Submissions by Patentees on Level of Therapeutic Improvement
• Patentees Reporting on R&D and Sales for 2014
•  Foreign Price Verification Policy
• Change in Foreign Price Verification Policy
• Clarification: Existing Drug Products Subsequently Sold by Another Patentee
• Summary of the Board’s December 15, 2014 Meeting

For more information regarding the January 2015 PMPRB NEWSletter, please see the PMPRB website.